Clinical Trials Logo

Filter by:
NCT ID: NCT01378975 Completed - Malignant Melanoma Clinical Trials

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Start date: July 2011
Phase: Phase 2
Study type: Interventional

This open-label, single-arm, multicenter study will evaluate the efficacy and safety in patients with metastatic melanoma who developed brain metastases. Patients may or may not have received prior treatment for metastatic melanoma with brain metastases (except treatment with BRAF or MEK inhibitors). Patients will receive oral doses of 960 mg vemurafenib twice daily until disease progression, unacceptable toxicity or consent withdrawal.

NCT ID: NCT01378910 Completed - HIV Clinical Trials

Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia

Start date: June 2011
Phase: Phase 4
Study type: Interventional

CCR5 antagonists might be an adequate alternative for HIV-1-infected individuals with suppressed viremia who experience antiretroviral-related toxicity. The assessment of HIV-1 tropism in proviral DNA could be helpful to inform in which of these subjects CCR5 antagonists could be efficacious.

NCT ID: NCT01377922 Completed - Clinical trials for Lambert Eaton Myasthenic Syndrome

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Start date: June 2011
Phase: Phase 3
Study type: Interventional

A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

NCT ID: NCT01377792 Completed - Cystic Fibrosis Clinical Trials

Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis

Start date: March 2009
Phase: Phase 4
Study type: Interventional

A phase IV clinical trial, multicentric (3 Hospitals in Madrid) controlled, prospective, open and randomized of long-term treatment with hypertonic saline in cystic fibrosis patients. The purpose of this study is to verify if the long term inhalation (48 weeks) of major volume (10 ml) increases the free time without pulmonary exacerbation, and if this increase is superior to the obtained with the inhalation of the standard volume (5 ml) that has been advocated.

NCT ID: NCT01377363 Completed - Breast Cancer Clinical Trials

Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis

Start date: December 11, 2009
Phase:
Study type: Observational

This is a Prospective Clinical Trial without drugs, to determine the HER2 status in the metastasis of patients with primary breast cancer HER2. 32 Sites have been taking part in this Clinical Trial.

NCT ID: NCT01377090 Completed - Systemic Sclerosis Clinical Trials

Digital Ulceration

CAP
Start date: January 2011
Phase: N/A
Study type: Observational

The CAP study is a multicenter, observational, clinical study in patients with systemic sclerosis. The study aims at determining the usefulness of nailfold videocapillaroscopy and patient-specific disease-related factors in predicting the occurrence of digital ulcers within a 6-month observation period. Patients with cutaneous forms of systemic sclerosis (limited or diffuse), with or without history of digital ulceration are eligible. The study will enroll 500 patients at 70 centers.

NCT ID: NCT01376999 Completed - Clinical trials for No Explained Sterility

Step Up Versus Step Down in Controlled Ovarian Stimulation

Start date: April 2010
Phase: Phase 4
Study type: Interventional

The aim of the study is to evaluate if the Step up protocol is equal or superior regarding efficacy and security than the step down protocol. In couple submitted two intrauterine insemination.

NCT ID: NCT01376921 Completed - Growth Disorders Clinical Trials

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain

ECOS ESP
Start date: September 30, 2012
Phase: N/A
Study type: Observational

This is a Spanish, Multicentre, Observational Study to study adherence and long term outcomes of therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment to assess the level of adherence of subject receiving SAIZEN® via easypod™.

NCT ID: NCT01376804 Completed - Clinical trials for Kidney Transplantation, Cytomegalovirus Infections

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

Start date: July 2011
Phase: Phase 4
Study type: Interventional

This open-label, single arm study will evaluate the tolerability and efficacy of Valcyte (valganciclovir) in the prevention of cytomegalovirus disease in pediatric renal transplant recipients. After transplantation, patients (aged 4 months to 16 years) will receive Valcyte orally daily for up to 200 days post-transplant and will be followed for 52 weeks post-transplantation.

NCT ID: NCT01376401 Completed - Multiple Myeloma Clinical Trials

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Start date: July 2011
Phase: Phase 2
Study type: Interventional

This protocol corresponds to an open-label national phase II, multicenter, to assess efficacy (in terms of response rate and CR) and toxicity of bendamustine, bortezomib and prednisone (BVP) in 60 patients newly diagnosed MM. Patients in the absence of disease progression or unacceptable toxicity receive up to 9 cycles of BVP. The patients eligible for autologous transplant receive four cycles of BVP, hematopoietic stem cell collection and administration of two cycles BVP over followed by autologous transplant. In addition to the overall response rates, will also be analyzed time to progression (TTP), progression-free survival (PFS) and overall survival. Finally, the results will be compared with BVP with those obtained in 120 patients included in our protocol VMP GEM10MAS65. Patients will be evaluated at scheduled visits up to 3 periods of study: pretreatment, treatment and monitoring.